# Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections

> **NCT03543436** · PHASE3 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 29 (actual)

## Conditions studied

- Urinary Tract Infections

## Interventions

- **DRUG:** Temocillin
- **DRUG:** meropenem or imipenem

## Key facts

- **NCT ID:** NCT03543436
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-04
- **Primary completion:** 2020-10-29
- **Final completion:** 2020-12-14
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2025-11-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03543436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03543436, "Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT03543436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*